{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:17:03Z","timestamp":1791825423304,"version":"4.3.4"},"reference-count":103,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82470590"],"award-info":[{"award-number":["82470590"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"award":["82470590"],"award-info":[{"award-number":["82470590"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Scientific Research Program of FuRong Laboratory","award":["2025PT5016"],"award-info":[{"award-number":["2025PT5016"]}]},{"name":"Key Projects of the Health Commission of Hunan Province","award":["20256584"],"award-info":[{"award-number":["20256584"]}]},{"DOI":"10.13039\/501100012269","name":"Aid Program for Science and Technology Innovative Research Team in Higher Educational Institutions of Hunan Province","doi-asserted-by":"publisher","award":["2023-233"],"award-info":[{"award-number":["2023-233"]}],"id":[{"id":"10.13039\/501100012269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Start-up Fund of the First Affiliated Hospital, Hengyang Medical School University of South China","award":["NHFY-SP-2023-02"],"award-info":[{"award-number":["NHFY-SP-2023-02"]}]},{"award":["NHFY-SP-2023-02"],"award-info":[{"award-number":["NHFY-SP-2023-02"]}],"id":[{"id":"https:\/\/ror.org\/03mqfn238","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>UDP-glucuronosyltransferases (UGTs) are a key family of phase II metabolic enzymes in humans that play a central role in maintenance of metabolic homeostasis and drug disposition by catalyzing glucuronidation of endogenous and exogenous substances. UGT-mediated metabolism of antitumor drugs plays a dual role in tumor drug resistance, emerging as a hotspot in cancer therapy. This review outlines the structural characteristics, classification system, tissue distribution, and multilevel regulation of UGTs, with a focus on their bidirectional roles in tumor drug resistance, i.e., promotion of resistance through metabolic clearance and inhibition of resistance through metabolic activation. This review also discusses strategies of multidimensional tumor resistance intervention based on UGTs, and we also discussed the challenges in the clinical translation of current UGT-targeting strategies. To date, most data on UGTs were derived from in vitro and preclinical models; clinical validation remains limited, and the dual roles of UGTs are highly context-dependent. This review article provides a perspective for comprehensive understanding of UGT-mediated tumor resistance and offers theoretical foundations and practical directions for development of novel antitumor strategies.<\/jats:p>","DOI":"10.3390\/ijms27156955","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:57:56Z","timestamp":1785761876000},"page":"6955","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Dual Role of Human UDP-Glucuronosyltransferase-Mediated Metabolism in Tumor Drug Resistance: Mechanisms and Prospects"],"prefix":"10.3390","volume":"27","author":[{"given":"Zhike","family":"Wang","sequence":"first","affiliation":[{"name":"Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang 421001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhong","sequence":"additional","affiliation":[{"name":"Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang 421001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenran","family":"Ren","sequence":"additional","affiliation":[{"name":"Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang 421001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Shi","sequence":"additional","affiliation":[{"name":"Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang 421001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Fang","sequence":"additional","affiliation":[{"name":"Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang 421001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xiao","sequence":"additional","affiliation":[{"name":"Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang 421001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Liu","sequence":"additional","affiliation":[{"name":"Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang 421001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deliang","family":"Cao","sequence":"additional","affiliation":[{"name":"Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang 421001, China"},{"name":"Department of Oncology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zeng","sequence":"additional","affiliation":[{"name":"Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang 421001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.intimp.2017.03.015","article-title":"Primary and acquired resistance to PD-1\/PD-L1 blockade in cancer treatment","volume":"46","author":"Wang","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s13402-022-00707-3","article-title":"Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer","volume":"45","author":"Xian","year":"2022","journal-title":"Cell Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drup.2017.10.003","article-title":"Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins","volume":"32","author":"Genovese","year":"2017","journal-title":"Drug Resist. Updates"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.bcp.2012.01.030","article-title":"Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters","volume":"83","author":"Chen","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e478s","DOI":"10.6061\/clinics\/2018\/e478s","article-title":"DNA repair pathways and cisplatin resistance: An intimate relationship","volume":"73","author":"Rocha","year":"2018","journal-title":"Clinics"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: Mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"Siddik","year":"2003","journal-title":"Oncogene"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc3599","article-title":"Cancer drug resistance: An evolving paradigm","volume":"13","author":"Holohan","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1146\/annurev.pharmtox.40.1.581","article-title":"Human UDP-glucuronosyltransferases: Metabolism, expression, and disease","volume":"40","author":"Tukey","year":"2000","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.phrs.2017.05.001","article-title":"UDP-glucuronosyltransferases (UGTs) and their related metabolic cross-talk with internal homeostasis: A systematic review of UGT isoforms for precision medicine","volume":"121","author":"Yang","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2174\/138920008783331158","article-title":"The UDP-glucuronosyltransferases as oligomeric enzymes","volume":"9","author":"Finel","year":"2008","journal-title":"Curr. Drug Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00204-024-03929-6","article-title":"Insight into the structure, oligomerization, and the role in drug resistance of human UDP-glucuronosyltransferases","volume":"99","author":"Xue","year":"2025","journal-title":"Arch. Toxicol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"34450","DOI":"10.1038\/srep34450","article-title":"Inter-isoform Hetero-dimerization of Human UDP-Glucuronosyltransferases (UGTs) 1A1, 1A9, and 2B7 and Impacts on Glucuronidation Activity","volume":"6","author":"Yuan","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Fujiwara, R., Yokoi, T., and Nakajima, M. (2016). Structure and Protein-Protein Interactions of Human UDP-Glucuronosyltransferases. Front. Pharmacol., 7.","DOI":"10.3389\/fphar.2016.00388"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/j.1440-1681.1997.tb02718.x","article-title":"Structure and function of uridine diphosphate glucuronosyltransferases","volume":"24","author":"Meech","year":"1997","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/0024-3205(95)02073-R","article-title":"Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation","volume":"57","author":"Burchell","year":"1995","journal-title":"Life Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bcp.2015.04.020","article-title":"Roles of human UDP-glucuronosyltransferases in clearance and homeostasis of endogenous substrates, and functional implications","volume":"96","author":"Bock","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3109\/10409239109081125","article-title":"Roles of UDP-glucuronosyltransferases in chemical carcinogenesis","volume":"26","author":"Bock","year":"1991","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1124\/dmd.110.037192","article-title":"The development of UDP-glucuronosyltransferases 1A1 and 1A6 in the pediatric liver","volume":"39","author":"Miyagi","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"ref_20","first-page":"120","article-title":"UGT1A1 genotype-specific phase I and pharmacokinetic study for combination chemotherapy with irinotecan and cisplatin: A Saitama Tumor Board study","volume":"34","author":"Takano","year":"2013","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/hep.1840100207","article-title":"Enhanced acetaminophen toxicity in rats with bilirubin glucuronyl transferase deficiency","volume":"10","author":"Wells","year":"1989","journal-title":"Hepatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1124\/dmd.108.021428","article-title":"Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines","volume":"36","author":"Nakamura","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/carcin\/15.8.1549","article-title":"Glucuronidation of carcinogenic arylamines and their N-hydroxy derivatives by rat and human phenol UDP-glucuronosyltransferase of the UGT1 gene complex","volume":"15","author":"Orzechowski","year":"1994","journal-title":"Carcinogenesis"},{"key":"ref_24","first-page":"837","article-title":"Conditional immortalization of Gunn rat hepatocytes: An ex vivo model for evaluating methods for bilirubin-UDP-glucuronosyltransferase gene transfer","volume":"21","author":"Fox","year":"1995","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1210\/endo.142.2.7958","article-title":"Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members","volume":"142","author":"Turgeon","year":"2001","journal-title":"Endocrinology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3109\/03602530903205823","article-title":"UGT3A: Novel UDP-glycosyltransferases of the UGT superfamily","volume":"42","author":"Meech","year":"2010","journal-title":"Drug Metab. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"36205","DOI":"10.1074\/jbc.M807961200","article-title":"Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase","volume":"283","author":"Mackenzie","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1124\/mol.110.069336","article-title":"The novel UDP glycosyltransferase 3A2: Cloning, catalytic properties, and tissue distribution","volume":"79","author":"MacKenzie","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/jb\/mvae084","article-title":"Characterization of UGT8 as a monogalactosyl diacylglycerol synthase in mammals","volume":"177","author":"Ohba","year":"2025","journal-title":"J. Biochem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1124\/dmd.112.049197","article-title":"Tissue distribution and relative gene expression of UDP-glucuronosyltransferases (2B7, 2B15, 2B17) in the human fetus","volume":"41","author":"Johansson","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/0006-2952(88)90234-1","article-title":"Immunocharacterization of UDP-glucuronyltransferase isoenzymes in human liver, intestine and kidney","volume":"37","author":"Peters","year":"1988","journal-title":"Biochem. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e01154","DOI":"10.1002\/prp2.1154","article-title":"Quantitative analysis of the UDP-glucuronosyltransferase transcriptome in human tissues","volume":"11","author":"Zhou","year":"2023","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1124\/dmd.104.001321","article-title":"Analysis of substrate specificities and tissue expression of rat UDP-glucuronosyltransferases UGT1A7 and UGT1A8","volume":"33","author":"Webb","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1124\/mol.107.036871","article-title":"The human UDP-glucuronosyltransferase: Identification of key residues within the nucleotide-sugar binding site","volume":"72","author":"Patana","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1124\/dmd.105.004093","article-title":"Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases","volume":"33","author":"Luukkanen","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2174\/1389200054633853","article-title":"Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyl-transferases","volume":"6","author":"Zhou","year":"2005","journal-title":"Curr. Drug Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40246-021-00331-6","article-title":"Epigenetics and microRNAs in UGT1As","volume":"15","author":"Meng","year":"2021","journal-title":"Hum. Genom."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3109\/03602532.2014.973037","article-title":"Transcriptional regulation of human UDP-glucuronosyltransferase genes","volume":"46","author":"Hu","year":"2014","journal-title":"Drug Metab. Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1517\/17425255.2013.754010","article-title":"Nuclear receptors PXR and CAR: Implications for drug metabolism regulation, pharmacogenomics and beyond","volume":"9","author":"Chai","year":"2013","journal-title":"Expert. Opin. Drug Metab. Toxicol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/03602532.2022.2048846","article-title":"Regulation of human UDP-glycosyltransferase (UGT) genes by miRNAs","volume":"54","author":"Hu","year":"2022","journal-title":"Drug Metab. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"490","DOI":"10.2174\/1389200219666180307122945","article-title":"Regulation of Mammalian UDP-Glucuronosyltransferases","volume":"19","author":"Wang","year":"2018","journal-title":"Curr. Drug Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"114643","DOI":"10.1016\/j.biopha.2023.114643","article-title":"Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges","volume":"162","author":"Duan","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/14728222.2023.2235718","article-title":"The role of the ATP-Binding Cassette A1 (ABCA1) in neurological disorders: A mechanistic review","volume":"27","author":"Paseban","year":"2023","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2174\/1389450003349443","article-title":"P-glycoprotein as a drug target in the treatment of multidrug resistant cancer","volume":"1","author":"Lehne","year":"2000","journal-title":"Curr. Drug Targets"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3892\/ijo.2023.5567","article-title":"Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein (Review)","volume":"63","author":"Tian","year":"2023","journal-title":"Int. J. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.apsb.2019.12.001","article-title":"The gut microbiome: An orchestrator of xenobiotic metabolism","volume":"10","author":"Collins","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2174\/0113892002312369240703102215","article-title":"Role of Cytochrome P450 3A4 in Cancer Drug Resistance: Challenges and Opportunities","volume":"25","author":"Pandey","year":"2024","journal-title":"Curr. Drug Metab."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"\u00d6zkan, A., Stolley, D.L., Cressman, E.N.K., McMillin, M., DeMorrow, S., Yankeelov, T.E., and Rylander, M.N. (2021). Tumor Microenvironment Alters Chemoresistance of Hepatocellular Carcinoma Through CYP3A4 Metabolic Activity. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.662135"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1073\/pnas.0709662105","article-title":"The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP","volume":"105","author":"Yun","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.breast.2015.06.002","article-title":"Potential of overcoming resistance to HER2-targeted therapies through the PI3K\/Akt\/mTOR pathway","volume":"24","author":"Wilks","year":"2015","journal-title":"Breast"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-019-0635-y","article-title":"Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer","volume":"122","author":"Hunter","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_53","first-page":"3541","article-title":"Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues","volume":"53","author":"Albin","year":"1993","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Lu, L., Zhou, J., Shi, J., Peng, X.J., Qi, X.X., Wang, Y., Li, F.Y., Zhou, F.Y., Liu, L., and Liu, Z.Q. (2015). Drug-Metabolizing Activity, Protein and Gene Expression of UDP-Glucuronosyltransferases Are Significantly Altered in Hepatocellular Carcinoma Patients. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0127524"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.biopha.2014.08.012","article-title":"Influence of UGT1A1 gene methylation level in colorectal cancer cells on the sensitivity of the chemotherapy drug CPT-11","volume":"68","author":"Xie","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"ref_56","first-page":"2893","article-title":"UGT1A10 is responsible for SN-38 glucuronidation and its expression in human lung cancers","volume":"24","author":"Oguri","year":"2004","journal-title":"Anticancer. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/mol.62.3.608","article-title":"Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)","volume":"62","author":"Montminy","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/00498254.2016.1183061","article-title":"In vitro characterization of belinostat glucuronidation: Demonstration of both UGT1A1 and UGT2B7 as the main contributing isozymes","volume":"47","author":"Dong","year":"2017","journal-title":"Xenobiotica"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/jcph.625","article-title":"Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer","volume":"56","author":"Goey","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"ref_60","unstructured":"Pratt, V.M., Scott, S.A., Pirmohamed, M., Esquivel, B., Kattman, B.L., and Malheiro, A.J. (2012). Belinostat Therapy and UGT1A1 Genotype, Medical Genetics Summaries."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41589-022-01235-9","article-title":"Etoposide promotes DNA loop trapping and barrier formation by topoisomerase II","volume":"19","author":"Le","year":"2023","journal-title":"Nat. Chem. Biol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1124\/dmd.106.012732","article-title":"UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: Structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics","volume":"35","author":"Wen","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/dmd.31.5.589","article-title":"Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1","volume":"31","author":"Watanabe","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1080\/10408347.2021.2007469","article-title":"Epirubicin: Biological Properties, Analytical Methods, and Drug Delivery Nanosystems","volume":"53","author":"Luiz","year":"2023","journal-title":"Crit. Rev. Anal. Chem."},{"key":"ref_65","first-page":"686","article-title":"Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7","volume":"29","author":"Innocenti","year":"2001","journal-title":"Drug Metab. Dispos."},{"key":"ref_66","first-page":"8443","article-title":"Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: Reversal of resistance by food additives","volume":"63","author":"Cummings","year":"2003","journal-title":"Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/bjc.1996.368","article-title":"Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU\/ICRF 505","volume":"74","author":"Meikle","year":"1996","journal-title":"Br. J. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bcp.2003.07.019","article-title":"Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: Contribution of drug transport proteins","volume":"67","author":"Cummings","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1021\/acs.molpharmaceut.8b00387","article-title":"Gender Differences in the Hepatotoxicity and Toxicokinetics of Emodin: The Potential Mechanisms Mediated by UGT2B7 and MRP2","volume":"15","author":"Wu","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.taap.2012.08.032","article-title":"Coupling of UDP-glucuronosyltransferases and multidrug resistance-associated proteins is responsible for the intestinal disposition and poor bioavailability of emodin","volume":"265","author":"Liu","year":"2012","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.bcp.2012.07.009","article-title":"Human UDP-glucuronosyltransferases: Feedback loops between substrates and ligands of their transcription factors","volume":"84","author":"Bock","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.bcp.2010.09.008","article-title":"UDP-glucuronosyltransferase 1A6 overexpression in breast cancer cells resistant to methotrexate","volume":"81","author":"Selga","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0006-2952(03)00389-7","article-title":"Contribution of the Ah receptor to the phenolic antioxidant-mediated expression of human and rat UDP-glucuronosyltransferase UGT1A6 in Caco-2 and rat hepatoma 5L cells","volume":"66","author":"Schmohl","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Avery, J.T., Zhang, R., and Boohaker, R.J. (2021). GLI1: A Therapeutic Target for Cancer. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.673154"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nature13283","article-title":"The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation","volume":"511","author":"Zahreddine","year":"2014","journal-title":"Nature"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1021\/acschembio.8b01118","article-title":"GLI1-Inducible Glucuronidation Targets a Broad Spectrum of Drugs","volume":"14","author":"Zahreddine","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1476-4598-9-46","article-title":"Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation","volume":"9","author":"Raynal","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1124\/mol.114.091603","article-title":"Epirubicin upregulates UDP glucuronosyltransferase 2B7 expression in liver cancer cells via the p53 pathway","volume":"85","author":"Hu","year":"2014","journal-title":"Mol. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1124\/dmd.114.062380","article-title":"Induction of human UDP-Glucuronosyltransferase 2B7 gene expression by cytotoxic anticancer drugs in liver cancer HepG2 cells","volume":"43","author":"Hu","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1749-6632.2009.04114.x","article-title":"Potential role of UGT pharmacogenetics in cancer treatment and prevention: Focus on tamoxifen","volume":"1155","author":"Lazarus","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1124\/dmd.107.017145","article-title":"Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases","volume":"35","author":"Sun","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1186\/bcr1539","article-title":"Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants","volume":"8","author":"Sun","year":"2006","journal-title":"Breast Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.bcp.2006.01.004","article-title":"Quaternary ammonium-linked glucuronidation of trans-4-hydroxytamoxifen, an active metabolite of tamoxifen, by human liver microsomes and UDP-glucuronosyltransferase 1A4","volume":"71","author":"Ogura","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1734-1140(11)70499-6","article-title":"Natural and synthetic acridines\/acridones as antitumor agents: Their biological activities and methods of synthesis","volume":"63","author":"Dzierzbicka","year":"2011","journal-title":"Pharmacol. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.bcp.2006.07.035","article-title":"Induction of G2\/M phase arrest and apoptosis of human leukemia cells by potent antitumor triazoloacridinone C-1305","volume":"72","author":"Augustin","year":"2006","journal-title":"Biochem. Pharmacol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1124\/dmd.112.045401","article-title":"Role of human UDP-glucuronosyltransferases in the biotransformation of the triazoloacridinone and imidazoacridinone antitumor agents C-1305 and C-1311: Highly selective substrates for UGT1A10","volume":"40","author":"Bratton","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.biopha.2018.05.117","article-title":"Drug metabolizing enzymes and their inhibitors\u2019 role in cancer resistance","volume":"105","author":"Pathania","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"104565","DOI":"10.1016\/j.pestbp.2020.104565","article-title":"UDP-glycosyltransferases contribute to spirotetramat resistance in Aphis gossypii Glover","volume":"166","author":"Pan","year":"2020","journal-title":"Pestic. Biochem. Physiol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"111023","DOI":"10.1016\/j.cbi.2024.111023","article-title":"Inhibition of human UDP-glucuronosyltransferase enzyme by entrectinib: Implications for drug-drug interactions","volume":"395","author":"Yin","year":"2024","journal-title":"Chem. Biol. Interact."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"116355","DOI":"10.1016\/j.ejmech.2024.116355","article-title":"Natural products as non-covalent and covalent modulators of the KEAP1\/NRF2 pathway exerting antioxidant effects","volume":"270","author":"Culletta","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"107689","DOI":"10.1016\/j.pharmthera.2020.107689","article-title":"Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping","volume":"218","author":"Miners","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/dmd.120.000273","article-title":"Clinical Investigation of Metabolic and Renal Clearance Pathways Contributing to the Elimination of Fevipiprant Using Probenecid as Perpetrator","volume":"49","author":"Weiss","year":"2021","journal-title":"Drug Metab. Dispos."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"168378","DOI":"10.1016\/j.jmb.2023.168378","article-title":"Medicinal Chemistry and NMR Driven Discovery of Novel UDP-glucuronosyltransferase 1A Inhibitors That Overcome Therapeutic Resistance in Cells","volume":"436","author":"Osborne","year":"2024","journal-title":"J. Mol. Biol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jmb.2018.11.007","article-title":"Overcoming Drug Resistance through the Development of Selective Inhibitors of UDP-Glucuronosyltransferase Enzymes","volume":"431","author":"Osborne","year":"2019","journal-title":"J. Mol. Biol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1158\/1078-0432.CCR-11-2484","article-title":"Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: Implications of genetic variants on pharmacokinetics and hyperbilirubinemia","volume":"18","author":"Peer","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"51","DOI":"10.33696\/Signaling.5.112","article-title":"Teaching an Old Drug a New Trick: Targeting Treatment Resistance in Genitourinary Cancers","volume":"5","author":"Aguilar","year":"2024","journal-title":"J. Cell Signal"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s12104-018-9830-7","article-title":"Backbone assignment of the apo-form of the human C-terminal domain of UDP-glucuronosyltransferase 1A (UGT1A)","volume":"12","author":"Osborne","year":"2018","journal-title":"Biomol. NMR Assign."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ejmech.2017.02.049","article-title":"\u03b2-Lactam analogues of combretastatin A-4 prevent metabolic inactivation by glucuronidation in chemoresistant HT-29 colon cancer cells","volume":"130","author":"Malebari","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"178596","DOI":"10.1016\/j.ejphar.2026.178596","article-title":"Remodeling of androgen metabolism network mediated by UGT2B: A new perspective on treatment resistance in prostate cancer","volume":"1015","author":"Wang","year":"2026","journal-title":"Eur. J. Pharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"6701","DOI":"10.1158\/0008-5472.CAN-16-1518","article-title":"UGT2B17 Expedites Progression of Castration-Resistant Prostate Cancers by Promoting Ligand-Independent AR Signaling","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12104-023-10122-w","article-title":"(1)H, (13)C, (15)N Backbone and sidechain chemical shift assignments of the C-terminal domain of human UDP-glucuronosyltransferase 2B17 (UGT2B17-C)","volume":"17","author":"Sulekha","year":"2023","journal-title":"Biomol. NMR Assign."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"110711","DOI":"10.1016\/j.enzmictec.2025.110711","article-title":"Modulating UDP-glucuronosyltransferase activity: Mechanisms, clinical implications, therapeutic strategies, and future directions in drug development","volume":"190","author":"Allam","year":"2025","journal-title":"Enzym. Microb. Technol."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"D\u00edaz-Villamar\u00edn, X., Nieto-S\u00e1nchez, M.T., Mart\u00ednez-P\u00e9rez, M., Novo-Gonz\u00e1lez, P., Fern\u00e1ndez-Var\u00f3n, E., Torres-Garc\u00eda, A., Gonz\u00e1lez Astorga, B., Blancas, I., Cabeza-Barrera, J., and Mor\u00f3n, R. (2025). Dose-Limiting Toxicities and the Maximum Tolerated Dose of Irinotecan Based on UGT1A1 Genotypes: A Systematic Review. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17050542"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/15\/6955\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:21:00Z","timestamp":1785903660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/15\/6955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":103,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ijms27156955"],"URL":"https:\/\/doi.org\/10.3390\/ijms27156955","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]}}}